+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of the NOVA intracranial drug-eluting stent system in patients with intracranial atherosclerotic stenosis. This study is a prospective, multi-center, single-arm clinical trial conducted across about 50 centers in China, aiming to include 1000 participants who are suitable candidates for stent angioplasty. The trial will run from December 2022 to December 2030, focusing on patients with significant artery narrowing in the brain. All participants will receive the NOVA drug-eluting stent, which is designed to treat intracranial artery stenosis with a sirolimus-eluting coating and a rapid exchangeable balloon. The study includes ten visits starting from preoperative screening, the operation day, then follow-ups at 30 days, 3 months, 6 months, 1 year, and annually up to 5 years after the procedure. This schedule allows researchers to closely monitor the devices performance and patient outcomes over time. Participants will undergo various assessments during these visits, including evaluations for stroke, death, ischemic events, and revascularization related to the treated artery. Other measures include rates of stroke in different brain regions, transient ischemic attacks, restenosis, bleeding events, and quality of life assessments using tools like the modified Rankin Scale and EuroQol-5D. Safety, device defects, and long-term outcomes will be carefully tracked throughout the study period, which lasts up to five years after the operation.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
5 locations
R

Actively Recruiting

Researchers are studying the use of molecular typing in the treatment of advanced thyroid cancer through a real-world clinical study that includes both retrospective and prospective parts. The retrospective study looks back at patients treated from January 2020 to December 2023 in 24 hospitals, gathering data on treatment history, molecular test results, adverse reactions, and survival outcomes. The prospective study will enroll patients from January 2024 to April 2027 receiving precise treatments in the same hospitals. This study aims to understand how molecular typing can guide treatment in various types of advanced thyroid cancer, including differentiated, medullary, poorly differentiated, and anaplastic forms. Participants receive targeted drug treatments based on the type of gene mutations found in their cancer. These treatments include dabrafenib plus trametinib for BRAF V600E mutation, entrectinib or larotrectinib for NTRK mutation, pralsetinib or selpercatinib for RET fusion or mutation, anlotinib for medullary carcinoma without RET mutation, lenvatinib combined with anti-PD-1 antibody for patients without specific mutations or unable to afford precision therapy, and other targeted treatments based on identified targets. The study includes several patient groups defined by cancer type and suitability for radioiodine therapy. During the study, researchers will collect and analyze clinical data, molecular test results, medication regimens, and follow-up survival information up to about three years. Key outcomes measured include objective response rate, duration and time to response, disease control rate, progression-free survival, and overall survival. Safety and adverse reactions are also monitored. The study involves ongoing data collection and follow-up to assess how molecularly guided treatments affect advanced thyroid cancer management over time.

All AgesAll GendersPhase 4
8 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.

Age: 12Years +All GendersPhase 3
202 locations
O

Actively Recruiting

Psoriasis is a chronic, recurring inflammatory disease influenced by genetics and environmental factors, marked by skin lesions that can affect multiple organs. Researchers are evaluating the effectiveness of different treatments chosen by patients in real-world clinical settings, comparing phototherapy, traditional systemic therapies, and biologics among Chinese psoriasis patients. This observational study aims to gather real-world evidence under routine care without intervention. Patients diagnosed with psoriasis by dermatologists choose their preferred treatments, which may include phototherapy, traditional systemic drugs, or biologics. The study does not assign treatments but observes outcomes as patients follow their chosen therapies. Data collection is supported through a phone application called Psoriasis New World, and the study includes multiple centers. Participants will be assessed regularly for treatment effectiveness using measures such as the Psoriasis Area and Severity Index PASI, Physician and Investigator Global Assessments, Body Surface Area affected, and Dermatology Life Quality Index. Adverse events and laboratory tests, including liver function, will be monitored throughout up to 12 months. The primary outcome is the percentage of patients achieving complete skin clearance PASI 100 at 6 months, with additional follow-up evaluations at 12 months.

All AgesAll Genders
29 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of BR005-036C tablets compared to placebo in adults experiencing acute migraine attacks, including those with or without aura. This phase IIIII, multicenter, randomized, double-blind study aims to better understand how well BR005-036C works to relieve migraine symptoms and how it compares to placebo treatment. Participants are randomly assigned to take one of two doses of BR005-036C oral tablets or a matching placebo tablet. The study assesses the medications effects shortly after dosing, focusing on relief from pain and bothersome symptoms within two hours. The trial includes a treatment period with close monitoring for up to nine days after taking the study drug. During the study, participants will be monitored for migraine pain relief, freedom from symptoms, use of rescue medications, and functional ability after dosing. Researchers will track adverse events and other safety measures throughout the treatment period. The primary outcomes focus on pain freedom and symptom relief two hours after dosing, with additional assessments up to 48 hours. Participants involvement includes medication dosing and follow-up visits to assess their response and safety.

Age: 18Years +All GendersPhase 2Phase 3
83 locations
C

Actively Recruiting

Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer that has an ESR1 mutation. This study focuses on patients who have previously received ribociclib or palbociclib-based treatment and aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants will receive either 5 mg per day of oral lasofoxifene plus oral abemaciclib 150 mg twice daily, or fulvestrant 500 mg given intramuscularly on Days 1, 15, and 29, then once monthly thereafter, combined with oral abemaciclib 150 mg twice daily. The study is randomized and open-label, allowing comparison between these two treatment combinations over time. During the study, participants will be closely monitored for progression-free survival, objective response rate, overall survival, clinical benefit rate, duration and time to response, time to cytotoxic chemotherapy, quality of life using a specific breast cancer assessment tool, and the incidence of adverse events. The study includes various assessments and safety monitoring over approximately three years to evaluate these outcomes and the participants response to the treatments.

Age: 18Years +All GendersPhase 3
224 locations
T

Actively Recruiting

Researchers are evaluating the use of Toripalimab combined with neoadjuvant chemotherapy as an adjuvant treatment for triple-negative breast cancer TNBC. This phase II, prospective, single-arm, multi-center clinical trial aims to assess the pathologic complete response PCR rate along with the types and frequency of side effects. Secondary objectives include monitoring disease-free survival, progression-free survival, and objective response rate in participants. The treatment involves two phases of neoadjuvant chemotherapy combined with Toripalimab administered intravenously every three weeks. The first phase includes Epirubicin, Cyclophosphamide, and Toripalimab for six weeks, followed by Albumin-bound Paclitaxel plus Toripalimab for another six weeks. After four treatment cycles, participants undergo radical breast cancer surgery. Postoperative therapy depends on pathology results if PCR is achieved, immunotherapy with Toripalimab continues every three weeks for one year if not, chemotherapy combined with Toripalimab continues. Gene testing on biopsy tissue and blood samples for ctDNA testing are also performed before and after treatment. During the study, participants will have regular assessments including pathology evaluation and monitoring of side effects. Researchers will track treatment response and survival outcomes over two to three years. The total involvement includes neoadjuvant treatment, surgery, postoperative therapy, and follow-up to evaluate treatment effectiveness and safety. Careful monitoring ensures adherence and collection of important biological samples for ongoing analysis.

Age: 18Years - 70YearsFEMALEPhase 2
13 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of combining nimotuzumab, toripalimab, and chemotherapy to treat patients with locally advanced tonsillar cancer. This prospective, single-arm Phase II study aims to see if this combination can improve the pathological complete response rate and overall survival compared to historical data. Approximately 10 patients will be enrolled with a follow-up period extending up to five years after enrollment to monitor long-term outcomes. Participants receive nimotuzumab 400 mg, toripalimab 240 mg, nab-paclitaxel 260 mgm, and carboplatin through intravenous infusions every three weeks for 2 to 4 cycles. Each infusion lasts at least 60 minutes with careful monitoring for reactions. After 2 to 4 cycles of this neoadjuvant combination therapy, patients undergo endoscopy and imaging evaluation around day 42 to assess response. Throughout the study, participants will have assessments including pathological examination within 1 to 2 weeks after radical surgery to measure the pathological complete response rate, surgical margins, and major pathological response. Radiological response rates are evaluated after completing two treatment cycles, and functional status is assessed before surgery and at 1 month, 6 months, and 1 year post-surgery or concurrent chemoradiotherapy. Disease-free survival will be followed for up to 72 months. Participants must comply with study procedures and follow-up visits during this period.

Age: 18Years - 80YearsAll GendersPhase 2
1 location
E

Actively Recruiting

Researchers are evaluating ABO2011, alone or combined with Toripalimab, in patients with advanced solid tumors. This open-label, single-group study focuses on assessing safety, tolerability, how the drugs behave in the body, their effects, and early signs of how well they might work. The study includes adults who have progressed after previous treatments or require treatment for selected tumor types. Participants will receive ABO2011 by intratumoral injection either as monotherapy or in combination with Toripalimab. The study has two phases dose escalation and dose expansion. The monotherapy and combination therapy groups are assessed separately, with different timelines for safety monitoring after dosing. The combination therapy safety follow-up lasts longer than monotherapy. Participants receive treatment according to the study plan until criteria for discontinuation are met. During the study, participants undergo evaluations for dose-limiting toxicities, adverse events, serious adverse events, and laboratory test abnormalities for specified periods after dosing depending on the treatment group. Tumor response will be measured up to two years after consent. Safety and pharmacokinetic assessments are conducted throughout treatment and follow-up. The total study duration for each participant varies based on treatment and monitoring schedules.

Age: 18Years +All GendersPhase 1Phase 2
5 locations

1-10 of 18

1